MXCT Overview

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Wall Street analysts forecast MXCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MXCT is6.92 USD with a low forecast of 4.94 USD and a high forecast of 8.89 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MaxCyte Inc revenue for the last quarter amounts to 7.30M USD, decreased -16.02

MaxCyte Inc. EPS for the last quarter amounts to -0.09 USD, decreased -10.00

MaxCyte Inc (MXCT) has 114 emplpoyees as of March 25 2026.

Today MXCT has the market capitalization of 78.94M USD.